NewsBenzingaStifel mantiene la recomendación de compra para Kymera Therapeutics y eleva el precio objetivo a $152 Stifel mantiene la recomendación de compra para Kymera Therapeutics y eleva el precio objetivo a $152 Benzinga 2026.09.22 10:43 (GMT+0) Open on Benzinga Other news Why Is Snowflake Stock Surging Monday? 18 Globo Titles Heading To Netflix In Unprecedented Licensing Agreement ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment RBC Capital Maintains Outperform on Regions Financial, Lowers Price Target to $32 Wells Fargo Maintains Equal-Weight on Greif, Lowers Price Target to $88 Piper Sandler Maintains Overweight on GCM Grosvenor, Lowers Price Target to $14.5
